BioHealth News Archive
Mark your calendars now! 5th Annual Women Building Bio (Interactive Virtual Conference)
September 12, 2020 Special Guests Including: Dr. Michele McMurry-Hearth President and CEO, Biotechnology Innovation Organization (BIO) {iframe}https://ym-virginiabio.informz.net/informzdataservice/onlineversion/ind/bWFpbGluZ2luc3RhbmNlaWQ9OTQzNTc1NSZzdWJzY3JpYmVyaWQ9MTEwMzcyNjM5NA=={/iframe}
Read More
Biobuzz Directory – Altimmune Receives Award From U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients With Early COVID-19
GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from…
Read More
Emergent Bio inks five-year deal with J&J for manufacture of COVID-19 vaccine (NYSE:EBS) | Seeking Alpha
Emergent BioSolutions (NYSE:EBS) has closed a five-year agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals for large-scale drug substance manufacturing for J&J's SARS-CoV-2…
Read More
NYC Builds Bio | The City’s Premier Organization for Real Estate.
Across the country today, not just in Boston and San Francisco, in leading and emerging life science clusters, life sciences institutions and innovative companies…
Read More
ITI Enters into License Agreement with Ichor to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001 – BioHealth Capital Region
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor Medical Systems (“Ichor”),…
Read More
The Life Sciences Report: Summer 2020 | Wilson Sonsini Goodrich & Rosati – JDSupra
The latest issue of The Life Sciences Report features an interview with Matthew J. Meyer, the firm's chief client corporate development officer, who has…
Read More
Alex Philippidis, Genetic Engineering and Biotechnology News Senior News Editor, Guests on BioTalk
Alex Philippidis joins Rich Bendis on BioTalk to discuss the BioHealth Capital Region from a National viewpoint, other Hubs, and how the industry has…
Read More
Update on New JLABS Incubator in Washington, DC – Blog Post | JLABS
Our newest Johnson & Johnson Innovation JLABS location, JLABS @ Washington, DC, continues to move closer to opening later this year. We recently caught…
Read More
FDA Announces First of Its Kind Pilot Program to Communicate Patient Reported Outcomes from Cancer Clinical Trials | FDA
The U.S. Food and Drug Administration today launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE). Through a new…
Read More
Scientific Engagement Lead JLABS @ Washington, DC in Washington, District of Columbia | Non Operating Companies
Johnson & Johnson Innovation is recruiting a Scientific Engagement Lead of Johnson & Johnson Innovation JLABS. The goal of Johnson & Johnson Innovation is…
Read More
Scott Plank’s newest venture is in the world of organ transplantation – Baltimore Business Journal
Scott Plank's latest investment is in a company that aims to solve logistical challenges within the organ transplant industry. MediGO offers a hardware and…
Read More
Novavax charges ahead with $200M, David Mott appointed to board – Washington Business Journal
Novavax Inc. plans to advance its Covid-19 vaccine candidate with new additions to the company and about $200 million in new funds from selling…
Read MoreHemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia
Charlottesville, Va., June 24, 2020 – HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received clearance from the U.S. Food and…
Read More
Replicate Bioscience and Immunomic Therapeutics Form Collaboration to Combat Infectious Diseases and Cancers | Business Wire
ROCKVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--Replicate Bioscience, Inc. (“Replicate”), a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers, and Immunomic…
Read More
NIIMBL Announces Nine Project Recipients of $8.9M in Pandemic Response Efforts
NEWARK, Del., June 24, 2020 /PRNewswire/ -- Today, the National Institute for Innovation in Manufacturing Biopharmacueticals (NIIMBL) announces that they have identified nine projects to…
Read More